Genovis
25,95 SEK -3,53%1.674 investorer følger denne virksomhed
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Omsætning
158,23 mio.
EBIT %
34,27 %
P/E
27,61
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GENO
Daglig lav / høj pris
25,7 / 27,6
SEK
Markedsværdi
1,7 mia. SEK
Aktieomsætning
2,57 mio. SEK
Volumen
96 t
Finanskalender
Generalforsamling
15.05.2024
Delårsrapport
15.05.2024
Delårsrapport
20.08.2024
Delårsrapport
08.11.2024
Årsrapport
14.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Mikael Lönn | 14,5 % | 14,5 % |
State Street Bank And Trust Co, W9 | 8,4 % | 8,4 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Genovis AB: NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING
Genovis AB: Carthesian Therapeutics terminates Genovis Licence Agreement
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools